SCA
MDGL icon

Sassicaia Capital Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sassicaia Capital Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-900
Closed -$240K – 31
2024
Q1 		$240K Buy
+900
New +$212K 1.02% 22
2023
Q1 		– Sell
-2,500
Closed -$726K – 44
2022
Q4 		$726K Buy
+2,500
New +$245K 1.8% 14

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sassicaia Capital Advisers's MDGL Position: Q2 2024 in Review

Sassicaia Capital Advisers sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 900 shares — an estimated $240K sold.

Sassicaia Capital Advisers first reported a position in MDGL in Q4 2022 and held it in 2 quarters. The position peaked at $726K in Q4 2022. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • Sassicaia Capital Advisers reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 900 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $240K.
  • Sassicaia Capital Advisers first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Sassicaia Capital Advisers's Madrigal Pharmaceuticals position peaked at $726K in Q4 2022.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Sassicaia Capital Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.